Verve Therapeutics, Inc. (VERV): Price and Financial Metrics


Verve Therapeutics, Inc. (VERV): $14.25

0.46 (+3.34%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add VERV to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

VERV Stock Price Chart Interactive Chart >

Price chart for VERV

VERV Price/Volume Stats

Current price $14.25 52-week high $78.00
Prev. close $13.79 52-week low $11.30
Day low $13.79 Volume 506,800
Day high $14.43 Avg. volume 679,236
50-day MA $19.47 Dividend yield N/A
200-day MA $38.12 Market Cap 693.42M

Verve Therapeutics, Inc. (VERV) Company Bio


Verve Therapeutics, Inc. is a genetic medicines company engaged in the development of a new approach to the care of cardiovascular disease. It aims to transform treatment from chronic management to single-course gene editing medicines. Its goal is to disrupt the chronic care model for CVD by providing a new therapeutic approach with single-course in vivo gene editing treatments focused on addressing the root causes of this highly prevalent and life-threatening disease.


VERV Latest News Stream


Event/Time News Detail
Loading, please wait...

VERV Latest Social Stream


Loading social stream, please wait...

View Full VERV Social Stream

Latest VERV News From Around the Web

Below are the latest news stories about Verve Therapeutics Inc that investors may wish to consider to help them evaluate VERV as an investment opportunity.

Verve Therapeutics (VERV) Presents At 40th Annual J.P. Morgan Virtual Healthcare Conference

No summary available.

Seeking Alpha | January 24, 2022

Verve Therapeutics Announces 2022 Anticipated Milestones and Preclinical Data on Potential Additional Dosing Regimens for its Novel Base Editing Programs

VERVE-101 Regulatory Submissions and First Patient Treated On-track for Second Half of 2022 ANGPTL3 Program Initiation of IND-Enabling Studies Expected in the Second Half of 2022 Preclinical Data in Non-Human Primates Demonstrate Potential to Re-Dose or Sequentially Dose Base Editing Programs CAMBRIDGE, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc., (Nasdaq: VERV), a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene

Yahoo | January 10, 2022

Verve Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 4:30 p.m. ET. A live webcast will be available in the investor section of the company's website at www.vervetx.com. The w

Yahoo | January 3, 2022

Verve Therapeutics Inc Insiders are Selling. Investors Should Take Notice

GuruFocus data shows that Sekar Kathiresan, CEO of Verve Therapeutics Inc ( NA:VERV), sold 48.693 shares on December 28, 2021.

Yahoo | December 29, 2021

3 Synthetic Biology Stocks in Focus With Strong Potential

Here we discuss three stocks - CDXS, PGEN, VERV - engaged in the field of scientific biology that investors may keep a tab of as these have the potential to generate wealth for them going forward.

Yahoo | December 24, 2021

Read More 'VERV' Stories Here

VERV Price Returns

1-mo N/A
3-mo -52.83%
6-mo -65.48%
1-year N/A
3-year N/A
5-year N/A
YTD -61.35%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.91 seconds.